AVBP · NASDAQ · Biotechnology

ArriVent BioPharma (AVBP)

Develops licensed oncology assets led by firmonertinib and antibody-drug conjugates.

$30.87
After hours+0.52 (+1.70%)
At close$30.35(+2.05%)